Skip to main content Skip to footer

Cardiology

Baylor Scott & White Medical Center - Temple

Comprehensive cardiology care

Baylor Scott & White – Temple is a comprehensive program offering a range of surgery for mitral valve disease through replacement, mitraclip, assist devices and transplantation. We also have experience with the treatment of aortic valve disease with the use of transcatheter aortic valve replacement (TAVR). Our center has been a referral center for central Texas for TAVR procedures since 2012.  We have performed over 750 procedures and our center acts as a teaching institution, training other centers in performing the procedure.

Conditions we treat include:

  • Aortic valve stenosis
  • Aortic valve regurgitation
  • Mitral valve disease
  • Mitral valve stenosis
  • Mitral valve regurgitation
{6}

Cardiac rehabilitation

Cardiac rehabilitation is a program designed to help improve your overall health by identifying and reducing the risk factors that lead to cardiovascular disease. As a participant in the cardiac rehab program, you will work with an exercise physiologist or registered nurse who will help you meet your personal goals.

We have a large team of people who specialize in the various aspects of recovery who will work with you, teach you and instruct you on the best practices for your recovery.  Follow up visits in the clinic are as early as 1 week after surgery.

{6}

Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure that offers an alternative to traditional open heart surgery for aortic stenosis. This approach avoids a sternotomy, the use of the heart-lung machine, and allows a quicker recovery. The procedure is performed by a team of physicians, including a cardiologist and a cardiac surgeon. A tissue valve is then deployed in position pushing the native diseased valve and the calcium aside.

Initially, TAVR was only reserved for high-risk patients, who were not candidates for open surgery. As experience with TAVR has increased and the results have been acceptable, its use has been expanded to include lower-risk patients as well as deemed appropriate by the heart team.

{6}
Scroll To Top